Media
Press releases
20Apr
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
19Apr
Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) application for Phase 3 study of imlifidase in anti-GBM disease
08Apr
Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update
Media assets
Executive Leadership Team
Dr Christian Kjellman
Senior Vice President, Chief Scientific Officer, Research and Development
